CTRI/2026/07/113506进行中（未招募）1 期
An open-label, single-treatment, single-period, single dose, clinical Phase-1 study to assess the safety and tolerability of Measles, Mumps, Rubella & Varicella Vaccine (live attenuated, freeze dried) of m/s. Zydus Lifesciences ltd. in Healthy, Adult, Human participants. - NIL
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male and non-pregnant, non-lactating female participants aged between 18 and 50 years (Both inclusive).
- •Body weight greater than 50 kg for male and greater than 45 kg for female and BMI within the range 18.5 to 30.0 kg/m2 (Both inclusive).
- •Ability to communicate effectively with study personnel.
- •Willingness to adhere to the protocol requirements.
- •Be able to give written informed consent for participation in the trial.
- •6.Normal health as determined by personal medical/surgical history, vaccination history, vital signs, physical examination, Chest X-ray PA view (only if clinically indicated), ECG and laboratory assessment data during screening (within the clinically acceptable range).
- •7.Male participants must agree to use effective contraception till study completion.
- •8.Female participants of childbearing potential must agree to use effective contraception till study completion.
- •9.Participant should be literate enough to understand study requirements and fill the diary card.
排除标准
- •Participants with known hypersensitivity to any component of the study vaccine
- •History of any hypersensitivity reaction, anaphylaxis or serious reactions to egg proteins, neomycin, albumin, gelatin or gelatin containing product.
- •Participants who are taking immunostimulant therapy (e.g., interferons) or immunosuppressant medications (e.g., corticosteroids, cytotoxic drugs or antimetabolites, etc.).
- •Participants who are known to be suffering from diseases which can affect immune competence e.g., diabetes, immunodeficiency disorders or known to be HIV positive.
- •Participants who have received immunoglobulins parenterally during the preceding 3 months of screening.
- •Participants who have received any vaccine in the preceding 1 month and who are planning to take vaccine during study period.
- •History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease, gynecological or any other body system involvement which interferes with safety assessment as per investigator discretion.
- •History or presence of significant alcoholism or drug abuse within the past one-year.
- •History or presence of significant smoking (more than 10 cigarettes per day) or consumption of tobacco product.
- •Blood pressure less than 100/60 (Systolic/diastolic) mm Hg or more than 140/90 (Systolic/diastolic) mm Hg.
- •Pulse less than 60/minute or more than 100/minute.
- •History of fever or any other infection in last 2 weeks of enrolment
- •Any clinically significant ECG abnormalities at screening.
- •Any clinically significant abnormal laboratory values during screening.
- •Participants who have participated in clinical research studies within past 3 months.
- •History of Blood donation or receipt of blood-derived products (e.g. plasma) within past 3 months prior to screening.
- •A positive urine drugs of abuse test or positive alcohol test at check-in.
- •For female participants, positive serum -hCG level at screening or urine pregnancy test at check-in visit.
- •Female participants with history of pregnancy or lactation in the past 3 months.
- •Female participants with history of less than 1 year of menopause and not using adequate contraceptive measures.
研究组 & 干预措施
Intervention1: MMRV vaccine: Dose:0.5 mL
干预措施: Intervention1: MMRV vaccine: Dose:0.5 mL
研究者
相似试验
招募中
4 期
An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.2025-522921-37-00Gebro Pharma GmbH36
招募中
2 期
An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseasesANCA associated vasculitis (AAV)Immune thrombocytopenic purpura (ITP)Multiple sclerosis (MS)Rheumatoid arthritis (RA)Pemphigus vulgaris (PV)Systemic sclerosis (SSc)Inflammatory idiopathic Myositis (IIM)2024-519491-60-00Universitaetsklinikum Tuebingen AöR36
已完成
1 期
An open label, randomized, single-dose, two-sequence, two-period, crossover comparative bioavailability study to assess the pharmacokinetic and safety profile of Dofetilide intravenous solution compared to Tikosyn® (Dofetilide) oral capsule in healthy subjects under fasting conditions.This study is a phase I trial, a single-dose, open label, randomized, two-period, two-sequence, crossover bioavailability study comparing IV to oral Dofetilide.2023-510176-31-00Hyloris Developments20
招募中
4 期
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on two amoxicillin-clavulanic acid film-coated tablet formulations in healthy volunteers under fed conditions.infections2025-521718-24-00Tarchominskie Zaklady Farmaceutyczne Polfa S.A.56
已完成
4 期
An open label, randomized, three-period, three-sequence, crossover bioavailability study to assess the pharmacokinetic and safety profile of Valacyclovir Oral Suspension compared to Valtrex® extemporaneous suspension in normal, healthy subjects under fasting conditions and to investigate the effect of food on the bioavailability of Valacyclovir Oral Suspension.Not applicable (submitted trial is a bioequivalence study in healthy subjects)2023-504760-42-00Dermax30